Use of highly concentrated polyunsaturated fatty acids for prevention after myocardial infarction. Cost-utility analysis

Plavinskii S. L.
MD, PhD, DSc., Head, Department of Teaching, Philosophy and Law¹

Barinova A. N.
MD, PhD, Associated Professor, Department of Family Medicine¹

1 - Federal State Budgetary Educational Institution for Higher Training «North-Western State Medical University named after I.I. Mechnikov» Ministry of Health of the Russian Federation

Sviatoslav L. Plavinskii, E-mail: s.plavinskij@szgmu.ru

Use of highly concentrated ethyl esters of polyunsaturated fatty acids after myocardial infarction and in patients with heart failure was associated with lower mortality. The goal of this analysis was to perform cost-utility analysis of the use of highly concentrated ethyl esters of polyunsaturated fatty acids after myocardial infarction (applying Markov model) and to find whether its use in some group of patients leads to decrease in budget costs. It was shown that use of highly con-centrated ethyl esters of polyunsaturated fatty acids after myocardial infarction leads to increase in quality-adjusted life expectancy on 0.5 QALY, with incre-mental cost-effectiveness ratio of 105 thousand rubles, and net monetary benefit of 780.5 thousand rubles. In the patient subpopulation that receives highly concen-trated ethyl esters of polyunsaturated fatty acids for arrhythmia prevention after coronary artery bypass the budget cost actually decrease, depending on denomina-tor used – on 6-50%.

myocardial infarction, cardiovascular mortality, polyunsaturated fatty acids, cost-utility analysis, quality-adjusted life years (QALY)

10.29234/2308-9113-2017-5-4-8-20

1. «Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial.» The Lancet 354, no. 9177 (1999): 447-55. doi:10.1016/s0140-6736(99)07072-5.

2. Rizos, Evangelos C., Evangelia E. Ntzani, Eftychia Bika, Michael S. Kostapanos, and Moses S. Elisaf. «Association Between Omega-3 Fatty Acid Supplementation and Risk of Major Cardiovascular Disease Events.» Jama 308, no. 10 (2012): 1024. doi:10.1001/2012.jama.11374.

3. Rizos, Evangelos C., and Moses S. Elisaf. «Does Supplementation with Omega-3 PUFAs Add to the Prevention of Cardiovascular Disease?» Current Cardiology Reports 19, no. 6 (2017). doi:10.1007/s11886-017-0856-8.

4. Investigators, Gissi-Hf. «Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.» The Lancet 372, no. 9645 (2008): 1223-230. doi:10.1016/s0140-6736(08)61239-8.

5. Yokoyama, M., H. Origasa, and M. Matsuzaki. «Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis.» The Lancet 369, no. 9567, 1090-098.

6. Galan, P., E. Kesse-Guyot, S. Czernichow, S. Briancon, J. Blacher, and S. Hercberg. «Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial.» Bmj 341, no. Nov 29 1 (2010): C6273. doi:10.1136/bmj.c6273.

7. Kromhout, Daan, Erik J. Giltay, and Johanna M. Geleijnse. «N–3 Fatty Acids and Cardiovascular Events after Myocardial Infarction.» New England Journal of Medicine 363, no. 21 (2010): 2015-026. doi:10.1056/nejmoa1003603.

8. Rauch, B., R. Schiele, S. Schneider, F. Diller, N. Victor, H. Gohlke, M. Gottwik, G. Steinbeck, U. Del Castillo, R. Sack, H. Worth, H. Katus, W. Spitzer, G. Sabin, and J. Senges. «Response to Letters Regarding Article, »OMEGA, A Randomized, Placebo-Controlled Trial to Test the Effect of Highly Purified Omega-3 Fatty Acids on Top of Modern Guideline-Adjusted Therapy After Myocardial Infarction«.» Circulation 124, no. 1 (2011). doi:10.1161/circulationaha.111.027243.

9. ORIGIN Trial Investigators, Bosch, J., Gerstein, H. C. et al. «N–3 Fatty Acids and Cardiovascular Outcomes in Dysglycemia.» New England Journal of Medicine 367, no. 18 (2012): 1760-761. doi:10.1056/nejmc1210552.

10. Roncaglioni, M. C., M. Tombesi, and F. Avanzini. «N−3 Fatty Acids in Patients with Multiple Cardiovascular Risk Factors.» New England Journal of Medicine 368, no. 22 (2013): 2146. doi:10.1056/nejmx130018.

11. Christou, Georgios, Konstantinos Christou, Panagiotis Korantzopoulos, Evangelos Rizos, Dimitrios Nikas, and John Goudevenos. «The Current Role of Omega-3 Fatty Acids in the Management of Atrial Fibrillation.» International Journal of Molecular Sciences 16, no. 9 (2015): 22870-2887. doi:10.3390/ijms160922870.

12. Ramsden, Christopher E., Joseph R. Hibbeln, Sharon F. Majchrzak, and John M. Davis. «N-6 Fatty acid-specific and mixed polyunsaturate dietary interventions have different effects on CHD risk: a meta-analysis of randomised controlled trials.» British Journal of Nutrition 104, no. 11 (2010): 1586-600. doi:10.1017/s0007114510004010.

13. Sin'kova, M. N., L. K. Isakov, N. I. Tarasov, and A. T. Teplyakov. «Otdalennye ehffekty vliyaniya omega-3 polinenasyshchennyh zhirnyh kislot na techenie ishemicheskoj bolezni serdca u bol'nyh, perenesshih infarkt miokarda s pod»emom segmenta ST na fone mnogososudistogo stenoziruyushchego ateroskleroza koronarnyh arterij [Long-term effects of the influence of omega-3 polyunsaturated fatty acids on the course of coronary heart disease in patients who underwent myocardial infarction with ST-segment elevation on the background of multivessel stenosing coronary artery atherosclerosis].« Kardiovaskulyarnaya terapiya i profilaktika 13, no. 6 (2014): 32-37.

14. Lamotte, Mark, Lieven Annemans, Pawel Kawalec, and York Zoellner. »A Multi-Country Health Economic Evaluation of Highly Concentrated N-3 Polyunsaturated Fatty Acids in Secondary Prevention after Myocardial Infarction.« PharmacoEconomics 24, no. 8 (2006): 783-95. doi:10.2165/00019053-200624080-00005.

15. Rudakova, A. V. »Farmakoehkonomicheskie aspekty primeneniya w-3 polinenasyshchennyh zhirnyh kislot v lecheniizabolevanij serdechno-sosudistoj sistemy [Pharmacoeconomic aspects of the use of w-3 polyunsaturated fatty acids in the treatment of cardiovascular diseases]. .« Klinicheskaya farmakologiya i terapiya 20, no. 3, 75-79.

16. Weinblatt, Eve, J. D. Goldberg, and W. Ruberman. »Mortality After First Myocardial Infarction.« Jama 247, no. 11 (1982): 1576. doi:10.1001/jama.1982.03320360026025.

17. Johansson, Saga, Annika Rosengren, Kate Young, and Em Jennings. »Mortality and morbidity trends after the first year in survivors of acute myocardial infarction: a systematic review.« BMC Cardiovascular Disorders 17, no. 1 (2017). doi:10.1186/s12872-017-0482-9.

18. Smolina, K., F. L. Wright, M. Rayner, and M. J. Goldacre. »Long-Term Survival and Recurrence After Acute Myocardial Infarction in England, 2004 to 2010.« Circulation: Cardiovascular Quality and Outcomes 5, no. 4 (2012): 532-40. doi:10.1161/circoutcomes.111.964700.

19. Zhang, Yu-Fei, Hong-Fang Gao, An-Ji Hou, and Yu-Hao Zhou. »Effect of omega-3 fatty acid supplementation on cancer incidence, non-vascular death, and total mortality: a meta-analysis of randomized controlled trials.« BMC Public Health 14, no. 1 (2014). doi:10.1186/1471-2458-14-204.

20. Costanzo, Simona, Veronica Di Niro, Augusto Di Castelnuovo, Francesco Gianfagna, Maria Benedetta Donati, Giovanni De Gaetano, and Licia Iacoviello. »Prevention of postoperative atrial fibrillation in open heart surgery patients by preoperative supplementation of n-3 polyunsaturated fatty acids: An updated meta-analysis.« The Journal of Thoracic and Cardiovascular Surgery 146, no. 4 (2013): 906-11. doi:10.1016/j.jtcvs.2013.03.015.

21. Calo, L., L. Bianconi, and F. Colivicchi. »N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial.« J. Am. Coll. Cardiol. 45, no. 10 (2005): 1723-728.

22. Permpanich, Adawan, Vithaya Kulsomboon, and Kamol Udol. »Cost-effectiveness analysis of highly concentrated n-3 polyunsaturated fatty acids in secondary prevention after myocardial infarction.« Asian Biomedicine 9, no. 1 (2015). doi:10.5372/1905-7415.0901.364.

23. Filipovic-Pierucci A., Zarca K., Durand-Zaleski I. Markov models for health economic evaluation: The R Package Heemod. ArXiv e-prints 2017. R package version 0.9.1. 1702.03252.

24. Yagudina, R. I., A. Yu Kulikov, and T. Nguen. »Opredelenie «poroga gotovnosti platit'» v Rossii, v Evropejskih stranah i v stranah SNG [Definition of the «threshold of willingness to pay» in Russia, in European countries and in the CIS countries].« Farmakoehkonomika 4, no. 1, 7-12.

25. Kolbin, A. S., E. A. Maksimkina, and A. A. Kurylev. »Stoimost' dopolnitel'noj ehffektivnosti protivoopuholevyh preparatov (po dannym ogranichitel'nyh spiskov) [Cost of additional efficacy of antitumor drugs (according to restrictive lists)].« Remedium, no. 11 (2016): 56-60.

26. Fox, Keith A A, Gordon Fitzgerald, Etienne Puymirat, Wei Huang, Kathryn Carruthers, Tabassome Simon, Pierre Coste, Jacques Monsegu, Philippe Gabriel Steg, Nicolas Danchin, and Fred Anderson. »Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outcomes using the updated GRACE risk score.« BMJ Open 4, no. 2 (2014). doi:10.1136/bmjopen-2013-004425.

27. Villareal, R.P, R. Hariharan, and B.C Liu. »Postoperative atrial fibrillation and mortality after coronary artery bypass surgery.« J. Am. Coll. Cardiol. 43, no. 5 (2004): 742-48. doi:10.1016/j.accreview.2004.06.058.

28. Mathew, Joseph P., R. Parks, and J. S. Savino. »Atrial Fibrillation Following Coronary Artery Bypass Graft Surgery.« Jama 276, no. 4 (1996): 300-06. doi:10.1001/jama.1996.03540040044031.